TrialNature medicine2022

Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial.

Jeremy Pettus et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.